FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Washington, D.C. 20040		

OMB APPROVAL		
OMB Number:	OMB Number: 3235-0287	
Estimated average burden		
hours per response:	0.5	

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

2. Issuer Name and Ticker or Trading Symbol 5. Relationship of Reporting Person(s) to Issuer 1. Name and Address of Reporting Person' (Check all applicable) Tyra Biosciences, Inc. [TYRA] Fuhrman Alan Director 10% Owner Officer (give title Other (specify 3. Date of Earliest Transaction (Month/Day/Year) below) below) (Middle) (Last) (First) 09/15/2023 Chief Financial Officer C/O TYRA BIOSCIENCES, INC. 4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable 2656 STATE STREET Line) Form filed by One Reporting Person X Form filed by More than One Reporting 92008 **CARLSBAD** CA Person Rule 10b5-1(c) Transaction Indication (City) (State) (Zip) Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 1. Title of Security (Instr. 3) 2. Transaction 2A. Deemed 5. Amount of 6. Ownership 7. Nature of Indirect Beneficial Execution Date, Transaction Securities Form: Direct (Month/Day/Year) if any Beneficially (D) or Indirect Code (Instr. (Month/Day/Year) 8) Owned Following (I) (Instr. 4) Ownership (Instr. 4) (A) or (D) Transaction(s) Price Code ٧ Amount (Instr. 3 and 4) 09/15/2023 A⁽¹⁾ Common Stock 1,463 A \$12.5035 1,463 D Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) 1. Title of 3. Transaction 3A. Deemed 5. Number 6. Date Exercisable and 7. Title and 8. Price of 9. Number of 10. 11. Nature Conversion Date (Month/Day/Year) Execution Date, Transaction Expiration Date (Month/Day/Year) of Indirect Derivative Security or Exercise if any Code (Instr. Securities Security Securities Form: Beneficial Price of Derivative Securities Acquired Underlying Derivative Beneficially Owned Direct (D) or Indirect Ownership (Instr. 4) (Instr. 3) (Month/Day/Year) 8) (Instr. 5) (A) or Disposed of (D) (I) (Instr. 4) Security Security (Instr. Following 3 and 4) Reported Transaction(s) (Instr. 3, 4 and 5) (Instr. 4)

Date

Exercisable

(A) (D)

Expiration

Date

Title

Explanation of Responses:

These shares were acquired under the Issuer's 2021 Employee Stock Purchase Plan

Remarks:

/s/ Ali D. Fawaz, Attorney-in-

Amount or Number

Shares

<u>Fact</u>

09/19/2023

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Code

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.